BIND Therapeutics, a biotech developing targeting mechanisms to enhance existing therapeutics, raised $71 million by offering 4.7 million shares at $15, within the range of $14 to $16. BIND Therapeutics plans to list on the NASDAQ under the symbol BIND. BIND Therapeutics initially filed confidentially on 6/28/2013. Credit Suisse and Cowen & Company acted as lead managers on the deal.
